Wells Fargo initiated coverage of Cytokinetics (CYTK) with an Overweight rating and $95 price target The firm expects Cytokinetics’ aficamten to post positive ACACIA data and unlock the nHCM market. Wells also expects commercial leadership for aficamten in oHCM due to simpler REMS and faster titration, as well as nHCM market syndergy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics management to meet with Citizens
- Cytokinetics price target raised to $95 from $87 at Barclays
- MYQORZO’s Differentiated Superiority in oHCM and De‑Risked Pipeline Support Buy Rating on CYTK
- Cytokinetics price target raised to $100 from $84 at Mizuho
- JPMorgan ups Cytokinetics target, adds to Analyst Focus List